128 related articles for article (PubMed ID: 38160916)
1. Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.
Neylon J; Ma TM; Savjani R; Low DA; Steinberg ML; Lamb JM; Nickols NG; Kishan AU; Cao M
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1181-1191. PubMed ID: 38160916
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
3. Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-Linac.
Muinck Keizer DM; Willigenburg T; der Voort van Zyp JRN; Raaymakers BW; Lagendijk JJW; Boer JCJ
Radiother Oncol; 2021 Sep; 162():162-169. PubMed ID: 34293410
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
6. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
[TBL] [Abstract][Full Text] [Related]
7. Assessment of intrafractional prostate motion and its dosimetric impact in MRI-guided online adaptive radiotherapy with gating.
Xiong Y; Rabe M; Nierer L; Kawula M; Corradini S; Belka C; Riboldi M; Landry G; Kurz C
Strahlenther Onkol; 2023 Jun; 199(6):544-553. PubMed ID: 36151215
[TBL] [Abstract][Full Text] [Related]
8. Soft-tissue prostate intrafraction motion tracking in 3D cine-MR for MR-guided radiotherapy.
de Muinck Keizer DM; Kerkmeijer LGW; Maspero M; Andreychenko A; van der Voort van Zyp JRN; van den Berg CAT; Raaymakers BW; Lagendijk JJW; de Boer JCJ
Phys Med Biol; 2019 Dec; 64(23):235008. PubMed ID: 31698351
[TBL] [Abstract][Full Text] [Related]
9. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac.
de Muinck Keizer DM; Kerkmeijer LGW; Willigenburg T; van Lier ALHMW; Hartogh MDD; van der Voort van Zyp JRN; de Groot-van Breugel EN; Raaymakers BW; Lagendijk JJW; de Boer JCJ
Radiother Oncol; 2020 Oct; 151():88-94. PubMed ID: 32622779
[TBL] [Abstract][Full Text] [Related]
10. Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial.
Hewson EA; Nguyen DT; O'Brien R; Poulsen PR; Booth JT; Greer P; Eade T; Kneebone A; Hruby G; Moodie T; Hayden AJ; Turner SL; Hardcastle N; Siva S; Tai KH; Martin J; Keall PJ
Radiother Oncol; 2020 Oct; 151():234-241. PubMed ID: 32828839
[TBL] [Abstract][Full Text] [Related]
11. DMLC tracking and gating can improve dose coverage for prostate VMAT.
Colvill E; Poulsen PR; Booth JT; O'Brien RT; Ng JA; Keall PJ
Med Phys; 2014 Sep; 41(9):091705. PubMed ID: 25186380
[TBL] [Abstract][Full Text] [Related]
12. Electromagnetic Transmitter-Based Prostate Gating for Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy: An Evaluation of Intrafraction Motion.
De Bari B; Guibert G; Slimani S; Bashar Y; Risse T; Guisolan N; Trouillot J; Abel J; Weber P
Curr Oncol; 2024 Feb; 31(2):962-974. PubMed ID: 38392066
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
[TBL] [Abstract][Full Text] [Related]
14. Intrafraction Motion Management of Renal Cell Carcinoma With Magnetic Resonance Imaging-Guided Stereotactic Body Radiation Therapy.
Prins FM; Stemkens B; Kerkmeijer LGW; Barendrecht MM; de Boer HJ; Vonken EPA; Lagendijk JJW; Tijssen RHN
Pract Radiat Oncol; 2019 Jan; 9(1):e55-e61. PubMed ID: 30261329
[TBL] [Abstract][Full Text] [Related]
15. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F
Radiat Oncol; 2020 Jul; 15(1):178. PubMed ID: 32698843
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
17. Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking.
Jaccard M; Ehrbar S; Miralbell R; Hagen T; Koutsouvelis N; Poulsen P; Rouzaud M; Tanadini-Lang S; Tsoutsou P; Guckenberger M; Zilli T
Radiother Oncol; 2021 Mar; 156():145-152. PubMed ID: 33310011
[TBL] [Abstract][Full Text] [Related]
18. Fiducial marker based intra-fraction motion assessment on cine-MR for MR-linac treatment of prostate cancer.
de Muinck Keizer DM; Pathmanathan AU; Andreychenko A; Kerkmeijer LGW; van der Voort van Zyp JRN; Tree AC; van den Berg CAT; de Boer JCJ
Phys Med Biol; 2019 Apr; 64(7):07NT02. PubMed ID: 30794995
[TBL] [Abstract][Full Text] [Related]
19. Prostate SBRT With Intrafraction Motion Management Using a Novel Linear Accelerator-Based MV-kV Imaging Method.
Gorovets D; Burleson S; Jacobs L; Ravindranath B; Tierney K; Kollmeier M; McBride S; Happersett L; Hunt M; Zelefsky M
Pract Radiat Oncol; 2020; 10(5):e388-e396. PubMed ID: 32454176
[TBL] [Abstract][Full Text] [Related]
20. Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer.
Wahlstedt I; Andratschke N; Behrens CP; Ehrbar S; Gabryś HS; Schüler HG; Guckenberger M; Smith AG; Tanadini-Lang S; Tascón-Vidarte JD; Vogelius IR; van Timmeren JE
Radiother Oncol; 2022 May; 170():205-212. PubMed ID: 35351536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
